MLMichelle A. Lowes

Michelle A. Lowes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle A. Lowes has a total of 504 co-authors. Here are the top co-authors by number of shared publications:

  • James G. Krueger

    Laboratory for Investigative Dermatology, Rockefeller University. New York, NY 10065, USA

    25 shared publications
  • James G. Krueger

    Laboratory for Investigative Dermatology The Rockefeller University New York New York USA

    18 shared publications
  • Judilyn Fuentes-Duculan

    Laboratory for Investigative Dermatology, Rockefeller University. New York, NY 10065, USA

    18 shared publications
  • Mayte Suárez-Fariñas

    Department of Population Health and Science Policy, Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

    17 shared publications
  • Irma Cardinale

    Laboratory for Investigative Dermatology, Rockefeller University, New York, NY

    14 shared publications
  • Lisa C. Zaba

    Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, United States of America

    14 shared publications

Latest Publications

  • Insights from HS PROGRESS, a longitudinal registry of patients with Hidradenitis Suppurativa

    by Valdemar Wendelboe Nielsen, Michelle A. Lowes, Ashley Yates, Afsaneh Alavi, R. Hal Flowers, Iltefat Hamzavi, Kristen E. Holland, Joslyn Kirby, Robert Micheletti, Gretchen M. Roth, et al.

  • B-cell/plasma cell gene coexpression modules enriched in hidradenitis suppurativa lesions and tunnels

    by Mika Yamanaka-Takaichi, Jaehwan Kim, Ching-Heng Chou, Tom C. Freeman, Ernesto Munoz, Victoria Fang, Dawn M. Waterworth, Monica W.L. Leung, Michael Cecchini, Michelle A. Lowes, et al.

  • Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens

    by Ashwath Jonathan Sampath, Linnea L. Westerkam, Franklin R. Blum, Raed Alhusayen, Falk G. Bechara, Julie Caffrey, Carmelo Carmona-Rivera, Nisha Suyien Chandran, Ralph George, Stephanie R. Goldberg, et al.


  • Global consensus process to establish a core dataset for hidradenitis suppurativa registries

    by Hannah E Wainman, Nisha S Chandran, John W Frew, Amit Garg, Angela Gibbons, Athena Gierbolini, Barbara Horvath, Gregor B Jemec, Brian Kirby, Joselyn Kirby, et al.

    Background: Several registries for hidradenitis suppurativa (HS) already exist in Europe and the USA. There is currently no global consensus on a core dataset (CDS) for these registries. Creating a global HS registry is challenging, owing to logistical and regulatory constraints, which could limit opportunities for global collaboration as a result of differences in the dataset collected. The solution is to encourage all HS registries to collect the same CDS of information, allowing registries to collaborate. Objectives: To establish a core set of items to be collected by all HS registries globally. The core set will cover demographic details, comorbidities, clinical examination findings, patient-reported outcome measures and treatments. Methods: Beginning in September 2022, 20 participants – including both clinicians with expertise in HS and patient advocates – from eight countries across three continents participated in a Delphi process consisting of four rounds of voting, with all participants completing each round. A list of potential items for inclusion in the core set was generated from the relevant published literature, including systematic reviews of comorbidities in HS, clinical and examination findings, and epidemiology. For disease severity and progression items, the Hidradenitis SuppuraTiva Core outcome set International Collaboration (HiSTORIC) core set and other relevant instruments were considered for inclusion. This resulted in 47 initial items. Participants were invited to suggest additional items to include during the first round. Anonymous feedback was provided to inform each subsequent round of voting to encourage consensus. Results: The eDelphi process established a CDS of 48 items recommended for inclusion in all HS registries globally. Conclusions: The routine adoption of this CDS in current and future HS registries should allow registries in different parts of the world to collaborate, enabling research requiring large numbers of participants.


  • Open Access

    External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort

    by Kelsey R. van Straalen, Thrasyvoulos Tzellos, Afsaneh Alavi, Farida Benhadou, Carlos Cuenca-Barrales, Mathilde Daxhelet, Mathieu Daoud, Ourania Efthymiou, Evangelos J. Giamarellos-Bourboulis, Philippe Guillem, et al.

    Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS patients. External validation is an important aspect of clinical outcomes. Objectives: We aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients. Methods: Data from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients were used to assess the association of IHS4-55 achievement with individual reduction in inflammatory nodules, abscesses, and draining tunnels. Moreover, the associations between IHS4-55 positivity and achievement of the minimal clinically important differences (MCIDs) for Dermatology Life Quality Index (DLQI), Numerical Rating Scale (NRS) Pain, and NRS Pruritus were analyzed. Results: Data were obtained from 283 individual patients, of which 36.4% (103/283) were treated with clindamycin and rifampicin and 63.6% (180/283) with tetracyclines for 12 weeks. Achievers of the IHS4-55 demonstrated a significant reduction the counts of inflammatory nodules, abscesses, and draining tunnels (all p < 0.001). Additionally, IHS4-55 achievers had an odds ratio for achieving the MCID of DLQI, NRS Pain, and NRS Pruritus of 2.16 (95% CI 1.28–3.65, p < 0.01), 1.79 (95% CI 1.10–2.91, p < 0.05), and 1.95 (95% CI 1.18–3.22, p < 0.01), respectively. Conclusions: This study shows the external validity of the novel IHS4-55 by demonstrating a significant association between IHS4-55 achievement and a reduction in inflammatory lesion counts as well as achievement of MCIDs for DLQI, NRS Pain, and NRS Pruritus in an antibiotic-treated cohort. These findings support the use of the IHS4-55 as a novel primary outcome measure in clinical trials.


  • Open Access

    Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

    by Jazzmin C. Williams, Raed Alhusayen, Sandra Guilbault, Nancy K. Hills, John R. Ingram, Margaret V. Kudlinski, Michelle A. Lowes, Angelo V. Marzano, Maia Paul, Bente Villumsen, et al.

    Key Message. HS patients on biologics have similar COVID-19 outcomes to those on nonbiologic therapy


  • Combining medical and surgical management strategies for hidradenitis suppurativa: Need for a treat to target approach

    by Michelle A. Lowes, Stephanie R. Goldberg, Afsaneh Alavi, Haley B. Naik

    For optimal management of hidradenitis suppurativa (HS), we propose a treat‐to‐target approach that synergizes medical and surgical therapies to improve outcomes and health‐related quality of life for HS patients. Studies are required to define the optimal targets in HS, however, proposed targets include disease remission or low disease activity. The goals of medical therapy in HS are to reduce existing inflammation and to prevent disease progression. The goals of surgical therapy are removal of permanently damaged fibrotic tissue and removal of biofilm within tunnels. In a treat‐to‐target approach, medical and surgical modalities are combined to optimize HS management. Regular and close monitoring are required to assess treatment response and achieve the predetermined target. Adjustments to the treatment plan can be made until the predetermined target is achieved. Research is needed to establish and evaluate this treat‐to‐target approach to help patients improve quality of life and achieve optimal disease control, and ultimately, disease remission.


  • Open Access

    Clinical considerations in the management of hidradenitis suppurativa in women

    by Emily K. Kozera, Michelle A. Lowes, Jennifer L. Hsiao, John W. Frew

    Hidradenitis suppurativa (HS) is a chronic, inflammatory disease of the skin with a predilection for women. The role of sex hormones, including estrogen and progesterone, is incompletely understood, but alterations in hormone levels may play a role in disease activity for many patients. Specific clinical considerations should be made for women with HS, particularly in the setting of pregnancy, childbirth, breastfeeding, and menopause. Current knowledge gaps regarding HS include the cumulative impact of disease across an individual's lifespan, as well as the mechanistic role of sex hormones in the disease. An improved understanding of the pathophysiologic role of hormones in HS would optimize our ability to use targeted therapies for hormonally driven disease. Psychological and psychosexual support for women with HS is an important facet of any holistic management strategy for the disease. This article integrates up-to-date pathogenic and mechanistic insights with evidence-based clinical management to optimize care for women with HS.


  • Open Access

    Hidradenitis Suppurativa Specialty Clinics in the USA

    by Justine R. Seivright, Alyssa Thompson, Iltefat Hamzavi, Michelle A. Lowes, Martina Porter, Vivian Y. Shi, Jennifer L. Hsiao

    Background: Hidradenitis suppurativa (HS) is a complex disease that is optimally managed with specialized care. Data on HS specialty clinics (HSSCs) are lacking. Methods: HSSCs in the USA were identified on the HS Foundation website and analyzed for geographic location and clinic director demographics. Results: We identified 29 HSSCs in 16 states, an increase from 22 in 2019. Thirty-four states currently lack a HSSC; the Mountain West and East South Central regions of the USA are particularly affected. Among HSSC directors, the majority (93.3%) are dermatologists, with slightly more women (53.3%) than men (46.7%). Most (86.7%) have an academic affiliation, and the majority (60%) graduated from residency <10 years ago. All directors are involved in research, and over half of HSSCs serve as HS clinical trial sites. Conclusions: The number of HSSCs in the USA has been growing, yet there remains a dearth in certain regions. Given that HS is a disease with high unmet need and a rapidly evolving therapeutic landscape, we encourage the establishment of more HSSCs to improve access to specialized care.


  • Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target

    by Afsaneh Alavi, Michelle A. Lowes, Justin D. Lu, Zhongli Xu, Maria Habel, Renfeng Guo, Vincent Piguet